NEW YORK, Oct. 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Hematological Cancers Drug Pipeline Update 2012
http://www.reportlinker.com/p0284919/Hematological-Cancers-Drug-Pipeline-Update-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity.
There are today 391 companies plus partners developing 617 hematological cancer drugs in 1222 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 191 drugs. Hematological Cancers Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 306 different targets. These targets are further categorized on in the software application by 67 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.
How May Drug Pipeline Update Be of Use?
* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc.
* Jump start competitive drug intelligence operations
* Excellent starting point for world wide benchmarking
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/out licensing strategy work
* Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug.
Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.
Drug Pipeline Update at a Glance
Investigators
Includes more than 391 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.
Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
Developmental stage
This Drug Pipeline Update contains 617 hematological cancer drugs in development, which have a total of 1222 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
Marketed# 85
Registered# 1
Pre-registration# 8
Phase III# 44
Phase II# 209
Phase I# 220
Preclinical# 204
No Data# 5
Suspended# 8
Ceased# 191
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications
Included hematological cancer drugs are also in development for 216 other indications, where of 88 are different cancer indications.
Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets
Identified drugs are linked to more than 306 different targets, divided into 67 classifications of molecular function:
- Acid phosphatase activity
- Antigen binding
- ATPase activity
- Auxiliary transport protein activity
- Carboxy-lyase activity
- Caspase activator activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Complement activity
- Cysteine-type peptidase activity
- Cytokine activity
- Deacetylase activity
- Deaminase activity
- Defense/immunity protein activity
- DNA binding
- DNA repair protein
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- DNA-methyltransferase activity
- G-protein coupled receptor activity
- Glutathione transferase activity
- Growth factor activity
- GTPase activator activity
- GTPase activity
- Hormone activity
- Hydrolase activity
- Isomerase activity
- Kinase activity
- Kinase binding
- Kinase regulator activity
- Ligand-dependent nuclear receptor activity
- Ligase activity
- Lipid kinase activity
- Lipid phosphatase activity
- Methyltransferase activity
- MHC class I receptor activity
- Molecular function unknown
- Motor activity
- Oxidoreductase activity
- Peptide hormone
- Phosphoric diester hydrolase activity
- Phosphorylase activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- RNA binding
- RNA-directed DNA polymerase activity
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- Superoxide dismutase activity
- T cell receptor activity
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity
Identified targets are categorized into 25 different primary and alternate sub-cellular localizations:
- Cell surface
- Centrosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Golgi apparatus
- Integral to membrane
- Lysosome
- Microtubule
- Mitochondrial membrane
- Mitochondrion
- Nuclear membrane
- Nucleolus
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Peroxisome
- Plasma membrane
- Secretory granule
- Soluble fraction
Note: You are able to find and sort drugs according to target gene name, molecular function of target, and target localization from drop-down menus in the application.
Target Expression Profile
Direct links are provided from inside the application to 388 protein expression profiles of 242 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals
Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG and NetPath.
- BioCarta# 244 Pathways
- KEGG# 174 Pathways
- NetPath# 25 Signaling Pathways
Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism
In total there are different drug mechanism of action represented in this Drug Pipeline Update.
Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound
Identified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Drug Profile
Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & Synonyms
Presentation of drug name and synonyms
Principal Investigator & Partners
Presentation of principal investigator and partners
Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol – Official Gene Name [Species/Homo Sapiens] – Molecular Function
Target Localization
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Targeted Pathways
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath.
Mechanism
Drug mechanism of action
Developmental Projects
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description
Short introduction to drug
Compound Data
Compound type, Chemical name, CAS Number and molecular weight
Patent Data
Available patent information related to the drug is presented here.
Business & Markets
Collaborations and deals
Approvals and submissions
Analyst comments
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II Data
Available Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Preclinical Data
Available preclinical development data, developmental history and scientific data.
Licensing Information
Availability for licensing
Application Features
Use 13 different parameters, available in drop-down menus, to find and sort among drugs
- Drug status
- Clinical Trial Status
- Principle Investigator
- Partners
- Indication
- Developmental Stage
- Compound Type
- Mechanism
- Target
- Molecular Function of Target
- Target Localization
- Targeted Pathways
- Free text search of entire drug profile contents
Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, and NetPath
- Direct links to company web pages of principal investigators
Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
System Requirements
- Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
To order this report:
Drug_and_Medication Industry: Hematological Cancers Drug Pipeline Update 2012
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
